Trial Profile
Vedolizumab Study With Inflammatory Bowel Disease Patients in Germany Documentation of Vedolizumab Induction and Maintenance Therapy in Conjunction With Long-term Outcome and Predictors of Response
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2022
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary) ; Adalimumab; Golimumab; Infliximab; Ustekinumab
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions
- Acronyms VEDOibd
- 01 Nov 2021 Interim results (n=295; cross-sectional analysis) assessing distinct profiles of patients with IBD in conjunction with unmet needs and decision-making for choosing a new biologic therapy published in the International Journal of Colorectal Disease
- 19 May 2020 Interim results (until 07/2019) published at the Digestive Disease Week 2020
- 28 Dec 2017 New trial record